Differences in lung bioavailability between different propellants for fluticasone propionate

Lancet. 1999 Oct 16;354(9187):1357-8. doi: 10.1016/S0140-6736(99)03581-3.

Abstract

The lung bioavailability (as adrenal suppression) of fluticasone propionate was about twofold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a microg equivalent may therefore be inadvisable.

Publication types

  • Clinical Trial
  • Comparative Study
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aerosol Propellants*
  • Androstadienes / pharmacokinetics*
  • Anti-Asthmatic Agents / pharmacokinetics*
  • Biological Availability
  • Chlorofluorocarbons*
  • Dose-Response Relationship, Drug
  • Fluticasone
  • Humans
  • Hydrocarbons, Fluorinated*
  • Hydrocortisone / urine
  • Lung / drug effects
  • Lung / metabolism
  • Single-Blind Method

Substances

  • Aerosol Propellants
  • Androstadienes
  • Anti-Asthmatic Agents
  • Chlorofluorocarbons
  • Hydrocarbons, Fluorinated
  • Fluticasone
  • apaflurane
  • Hydrocortisone